Waltham, MA. (OBBeC) - Genedata, a provider of in silico solutions for the pharmaceutical and life sciences industries, has reported that its Expressionist platform has expanded GeneChip-compatible status for Exon expression with the Affymetrix GeneChip microarray platform.

Genedata Expressionist is a modular enterprise system for biomarker discovery. It represents a single-point-of-access for experimental, proprietary and public data, including sample information, raw and pre-processed transcriptomics, proteomics, metabolomics and lab chemistry data, analysis results, reports and documentation.

Expressionist`s Refiner Array module performs high-throughput automated quality assessment and processing of Affymetrix GeneChip Exon data. Workflow-based processing supports validated working environments, while comprehensive reporting and documentation features ensure effective project management and communication. The high level of automation increases reproducibility and supports efficient handling of large experimental datasets, taking only a few seconds per array while scalability benchmarks demonstrate nearly linear scalability of processing 50, 100, 500 or 1,000 Exon chips at a time.

Dr. Othmar Pfannes, CEO of Genedata, said, “As a longtime Affymetrix partner, we are delighted to expand our collaboration, covering Affymetrix Exon chips. Refiner Array is an amazingly scalable solution that saves time, resources and cost in microarray analysis. The accurate processing and analysis of large datasets with high performance systems will pave the way to personalized medicine.”

“To truly understand biological systems, life scientists need to look beyond the 3’ end of a gene,” said Greg Fisher, Associate Director of Product Marketing, Systems and Software at Affymetrix. “The Affymetrix exon arrays provide a more complete and accurate view of a gene's total transcription activity compared to traditional expression array designs. The data management and analysis capabilities of Genedata’s Expressionist allow researches to make more informed decisions based on the roles alternative splicing and gene expression play in biology.”